Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Cord Blood Stem Cells in HLHS Patients Undergoing Norwood Operation
NCT03431480Phase 1Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Feb 2018
- Primary completion
- Nov 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous umbilical cord blood-derived mononuclear cells in hypoplastic left heart syndrome (HLHS), sponsored by Murdoch Children's Research Institute. Primary endpoint: Incidence of adverse cardiac events at 1 month. Started Feb 2018; status: completed.
02
Drugs
autologous umbilical cord blood-derived mononuclear cells
03
Conditions
hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT03431480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431480.